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Abstract
Background: Severe autoinflammatory diseases are associated with mutations in the Foxp3 locus in both mice and
humans. Foxp3 is required for the development, function, and maintenance of regulatory T cells (Tregs), a subset of
CD4 cells that suppress T cell activation and inflammatory processes. Siva is a pro-apoptotic gene that is expressed
across a range of tissues, including CD4 T cells. Siva interacts with three tumor necrosis factor receptor (TNFR)
family members that are constitutively expressed on Treg cells: CD27, GITR, and OX40.
Results: Here we report a biophysical interaction between FOXP3 and Siva. We mapped the interaction domains
to Siva’s C-terminus and to a central region of FOXP3. We showed that Siva repressed IL-2 induction by
suppressing IL-2 promoter activity during T cell activation. Siva-1’s repressive effect on IL-2 gene expression appears
to be mediated by inhibition of NFkappaB, whereas FOXP3 repressed both NFkappaB and NFAT activity.
Conclusions: In summary, our data suggest that both FOXP3 and Siva function as negative regulators of IL-2 gene
expression in Treg cells, via suppression of NFAT by FOXP3 and of NFkappaB by both FOXP3 and Siva. Our work
contributes evidence for Siva’s role as a T cell signalling mediator in addition to its known pro-apoptotic function.
Though further investigations are needed, evidence for the biophysical interaction between FOXP3 and Siva invites
the possibility that Siva may be important for proper Treg cell function.
Background
The transcription factor Foxp3 is essential for immune
system regulation due to its role in the development and
function of regulatory T cells (Tregs) [1,2]. The dramatic
autoimmune phenotype that is caused by mutated Foxp3
in both mice and humans led to its initial identification
[2,3]. In the absence of Foxp3, lethal autoimmunity ensues.
Sequencing of the FOXP3 genes from IPEX (Immune
polyendocrinopathy, enteropathy, X-linked) patients
revealed function ablating mutations throughout domains
critical for FOXP3 function [4,5]. The scurfy mouse is an
autoimmune mutant that has a spontaneous truncation
mutation in Foxp3. In addition to its well-studied role in
Tregs, an emerging body of work has revealed Foxp3 to be
a tumor suppressor in breast cancer [6,7]. Foxp3 activates
and suppresses a broad range of genes, but the mechan-
isms by which this happens are not well-understood
[8-10]. By understanding the relationship between FOXP3
and its binding partners, we hope to illuminate how
FOXP3 operates as a powerful regulator of immune
activation.
Already, FOXP3 is reported to reside in a supramolecu-
lar complex [11] and a number of specific interactions
have been identified [12]. Co-immunoprecipitation (Co-
IP) demonstrated binding between FOXP3 (or Foxp3) and
the following partners: the NFB p65 subunit [13], TIP60,
HDAC7, HDAC9 [14], FOXP1 [11], Runx1/AML1 [15],
t h eA P - 1c o n s t i t u e n t ,c J U N[ 1 6 ] ,R O R a [17], RORgt
[18,19], and Eos [20]. Also, Foxp3 homo-oligomerizes
[11,21]. Wu el al [22] demonstrated that Foxp3 inhibits
the transcriptional enhancing effects of NFAT and AP-1
by disrupting their interaction.
Regulation of IL-2 gene expression is critical to immune
tolerance, Treg development and Treg function [23,24].
Foxp3 inhibits IL-2 production in Tregs and confers IL-2
suppressive function in trans [25]. Even before Tregs and
Foxp3 became inextricably coupled, researchers investi-
gated the effect of Foxp3 on IL-2 transcription [26]. While
IL-2 is not the sole target of Foxp3 [9], coordinated inves-
tigations into molecular interactions localized to the IL-2
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understanding Foxp3’sf u n c t i o na sat r a n s c r i p t i o n a l
regulator.
Here we report a previously unidentified FOXP3 binding
partner, Siva. The novel interaction was exposed in a yeast
two-hybrid screen for FOXP3 binding partners. We were
interested in Siva for its known cell death promoting prop-
erties [27,28]. The possibility of a pro-apoptotic molecule
that might confer Treg properties was intriguing. Also, Siva
binds tumor necrosis factor receptor (TNFR) family mem-
bers associated with (but not exclusive to) the Treg surface
phenotype: CD27, GITR (glucocorticoid-induced TNFR-
related protein), and OX40 [27-33]. Siva was first identi-
fied based on its CD27-binding activity, which was
demonstrated by Co-immunoprecipitation (Co-IP) studies
in 293T cells transiently transfected with CD27 and GFP-
tagged Siva [27]. In a subsequent study, the same group
showed that the CD27 cytoplasmic tail mediated the inter-
action between both isoforms, Siva-1 and Siva-2 [28]. The
cytoplasmic region of CD27 shares a high degree of
homology with GITR, and OX40, which prompted the
investigation and confirmation that these other TNFR
family members also interact with Siva [29]. GITR is
highly expressed on Tregs and attributes suppressive prop-
erties under certain conditions [34,35]. In a transient
transfection system, Siva and GITR functionally interacted
to exacerbate apoptosis [29]. Thus, we investigated Siva
because of its pro-apoptotic properties and its ability to
bind TNFR family members that are associated with the
Treg surface phenotype.
Our data shows a physical interaction between FOXP3
and Siva protein exogenously expressed in 293T cells. We
mapped the FOXP3-interacting domain to the C-terminus
of Siva. The central portion of FOXP3 (amino acids (AAs)
106-332) contains Siva-binding activity. We found that
Siva repressed IL-2. The repressive effect of Siva on IL-2
appears to be mediated by NFB, as our data and others
show a negative regulatory effect for Siva on NFB activity
[36]. Consistent with previous reports [13,22], we observed
that FOXP3 repressed NFB and NFAT. To conclude,
while the pro-apoptotic effect of Siva has been thoroughly
demonstrated and documented, this analysis of Siva’s
effect on IL-2 contributes evidence for Siva’s role in T cell
signalling.
Results
Siva physically interacts with FOXP3
A yeast two-hybrid screen for FOXP3-binding partners
was performed with a human thymus cDNA library. Six
full-length clones for Siva-1 were identified in the screen.
We chose Siva-1 for further investigation for two reasons.
First, Siva regulates T cell apoptosis and, second, because
Siva associates with TNFR family members that might
contribute to Treg function: CD27, GITR, and OX40
[29-33].
We tested whether FOXP3 and Siva could interact in
mammalian cells. Two isoforms, Siva-1 and Siva-2 [28],
have been described and their protein domain organiza-
tion is depicted in Figure 1A [GenBank: NP_006418,
NP_068355]. Siva-2 lacks the second exon, resulting in a
protein that is missing most of the spherical amphipathic
helix (SAH) and death domain homology region (DDHR)
[28]. We performed co-immunoprecipitation (Co-IP)
experiments with transfected 293T cell lysates. We trans-
fected 293T cells with expression plasmids for EGFP-
tagged Siva isoforms and Myc-tagged FOXP3, or the
appropriate vector control. Myc/FOXP3 was immunopre-
cipitated with a mouse anti-Myc hybridoma supernatant,
9 E 1 0 .A ss h o w ni nF i g u r e1 B ,b yw e s t e r nb l o t t i n g( W B )
with an antibody against GFP, we detected Co-IP of Siva-1
and Siva-2 in the presence of Myc/FOXP3, but not in its
absence. EGFP alone did not Co-IP with FOXP3 (data not
shown). Thus both Siva-1 and Siva-2 specifically interact
with FOXP3.
Next, we wanted to know whether Siva was expressed in
FOXP3-expressing Treg cells. We examined Siva expres-
sion profiles contained within the microarray dataset gen-
erated by Fontenot et al. from Foxp3
GFP knock-in mice
[33]. Fontenot et al. sorted CD4
pos T cells for CD25 and
Foxp3
GFP. The data shown in Figure 1C demonstrates that
Siva is expressed in CD4
pos T cells that are both positive
and negative for Foxp3 expression. Siva is preferentially
associated with CD25, a marker associated with both the
Treg phenotype and T cell activation. Thus, Siva and
Foxp3 are co-expressed in mouse Tregs that express the
CD25 surface marker.
Siva-binding activity is contained within FOXP3’s central
region
Major domains of the FOXP3 protein are associated
with specific functional activities and binding partners
(Figure 2A) [GenBank: NP_054728, NP_001107849]
[12]. The Foxp3 N-terminus is required for NFAT-
mediated repression of IL-2 [22] and is involved in bind-
ing to the RORgta n dR O R a transcription factors [19].
The leucine zipper (L zip) domain mediates homodimer-
ization of Foxp3, which contributes to Treg suppressive
function [11,21]. The C-terminal Foxp3 forkhead (Fkh)
domain is required for DNA binding and nuclear locali-
zation [26]. A short stretch of amino acids between the
zinc finger (Zn F) and the Fkh domain is involved in
Runx1/AML1 binding and is involved in IL-2 repression
[15].
We used Myc/FOXP3 truncation mutants to charac-
terize the region involved in binding to Siva by Co-IP in
293T cells (summarized in Figure 2A). Mutants lacking
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Page 2 of 15the Fkh domain (ΔFkh) or the N-terminus (Δ1-71; Δ1-
105) bound to Siva with similar efficiency as full length
FOXP3 (Figure 2B). The FOXP3 Fkh mutant repeatedly
showed lower expression than other FOXP3 mutants
(Figure 2B and not shown). The reduced level of expres-
sion might have contributed to the lack of binding
between FOXP3 Fkh and EGFP/Siva-1. Still, based on
the Siva-binding activity of the ΔFkh mutant, we con-
clude that the FOXP3 Fkh domain is not necessary for
Siva-binding activity. FOXP3’s Siva-binding activity is
located within the protein’s central region (AAs 106-
332), which spans the leucine zipper, the zinc finger and
Runx1-binding domains.
The Siva C-terminus is sufficient to bind FOXP3
As shown in Figure 3A, we designed Siva truncation
mutants fused to EGFP’s C-terminus to cover major
domains that have been previously described and asso-
ciated with functional properties [27,28,37]. We per-
formed Co-IPs to map Siva’s FOXP3-binding activity.
Our analysis definitively showed no interaction between
FOXP3 and Siva mutants lacking the C-terminus (Figure
3B). In contrast, all mutants containing some portion of
the cysteine rich Siva C-terminal domain interacted with
FOXP3. Given that the Siva C-terminus mutant and the
ΔZn F mutant both contain the B box domain and both
interacted with FOXP3, we hypothesized that the Siva B
box domain might be necessary and sufficient to bind
FOXP3. To test our hypothesis, we designed mutants
encompassing the Siva B box domain and full length Siva
lacking the B box domain (ΔB box). Subsequent Co-IP
experiments demonstrated a very weak, but detectable
interaction between FOXP3 and the Siva B box domain.
The Siva ΔB box mutant was fully competent to bind
FOXP3. Thus, the Siva B box domain appears unneces-
sary and insufficient to bind FOXP3 (Figure 3C).
Siva negatively regulates IL-2 gene expression
We next investigated Siva’s effect on IL-2 gene expres-
sion. In order to evaluate the effect of Siva overexpres-
sion on endogenous IL-2, we transduced Jurkat T cells
with pHSP-EGFP/Siva-1 or pHSPG-Siva-1 retrovirus
Figure 1 FOXP3 physically interacts with both Siva isoforms. A. Diagram showing the Siva protein domain organization (SAH, spherical
amphipathic helix; DDHR, death domain homology region; and Zn F, zinc finger) and a cartoon representation of Siva-1 and Siva-2, which were
fused to the C-terminus of EGFP. B. Co-immunoprecipitation (Co-IP) to evaluate FOXP3’s interaction with Siva-1 and Siva-2 in 293T cells. Lysates
from 293T cells transfected with plasmids encoding EGFP/Siva fusion constructs and Myc/FOXP3 or vector were IP’ed with mouse anti-Myc 9e10
hybridoma supernatant. Western blot (WB) was performed with a mouse monoclonal antibody against GFP. Membranes were stripped and
reprobed with a rabbit anti-Myc polyclonal antibody. FOXP3 binding to Siva-1 was observed in seven independent experiments; FOXP3 binding
to Siva-2 was observed in three out of three experiments. C. Siva expression based on spot intensities for CD4
pos T cells isolated from the
Foxp3
GFP reporter mouse and sorted for both Foxp3
GFP and CD25 expression [33]. The data was generated on an Affymetrix Mouse Genome 430
2.0 array platform.
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Page 3 of 15Figure 2 Siva-binding activity is contained within a central portion of the FOXP3 protein (amino acids 106-332). A. Diagram depicting
FOXP3 protein domain organization and truncation mutants that were fused to the Myc C-terminus and used in the Co-IP shown in B. (bd,
binding domain; Zn F, zinc finger; L Zip, leucine zipper; Fkh, forkhead). B. Co-immunoprecipitation (Co-IP) to map FOXP3’s Siva-binding activity.
Co-IPs were performed as described in Figure 1. Binding between the FOXP3 Fkh mutant and Siva was tested three times. The other FOXP3
mutants shown here were tested once.
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Page 4 of 15Figure 3 The Siva C-terminus is sufficient to bind FOXP3. A. Diagram showing the Siva protein domain organization (SAH, spherical
amphipathic helix; DDHR, death domain homology region; B box; and Zn F, zinc finger) and Siva truncation mutants, which were fused to the
EGFP C-terminus and tested in Co-IPs shown in B and C. B. Co-IP to map Siva’s FOXP3-binding activity (hc, antibody heavy chain; lc, antibody
light chain). These Siva truncation mutants were tested three times for FOXP3-binding activity. C. Co-IP to test the FOXP3-binding activity of the
Siva B box and ΔB box mutants. These mutants were each tested twice for FOXP3-binding activity.
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used to measure cell viability and transduction efficiency.
This basic gating scheme was used in subsequent experi-
ments throughout this report. For each experiment,
GFP
neg cells were used to determine the position of all
gates and quadrant boundaries. We normalized IL-2
expression levels to viable cell counts in order to examine
Siva’s effect on IL-2 separate from Siva’s effect on apop-
tosis. The repressive effect of EGFP/Siva-1 and Siva-1 on
endogenous IL-2 in Jurkat T cells are shown in Figures
4B &4C, respectively. EGFP/Siva-1 repressed endogenous
IL-2 by nearly 90% compared to pHSPG transduced cells
(Figure 4B). In a separate experiment, overexpression of
Siva-1 also repressed endogenous IL-2 gene expression
(Figure 4C). Next, we tested the effect of Siva knockdown
(KD) on endogenous IL-2 gene expression (Figure 4D).
Jurkat T cells were transduced with pLKO lentivirus (LV)
expressing shSiva or shEGFP,a sac o n t r o ls h R N A .T h e
DNA gel confirms Siva KD based on RT-PCR using pri-
mers specific for both Siva isoforms. Siva KD enhanced
IL-2 gene expression compared to the shEGFP control,
providing further evidence that Siva a c t sa san e g a t i v e
regulator of IL-2 gene expression.
Siva negatively regulates IL-2 promoter activity
In addition to measuring Siva’s effect on endogenous IL-2
protein levels, we tested the effect of Siva gene expression
on IL-2 promoter activity. A minimal enhancer element
located 300 base pairs immediately upstream of the IL-2
start site regulates transcription through the binding of
transcription factors and alterations in the chromatin
structure [38,39]. Distal regulatory elements also contri-
bute to IL-2 gene regulation and the minimal enhancer
region is sometimes referred to as the proximal promoter.
In order to investigate Siva’s effect on IL-2 transcriptional
activation, we used a reporter plasmid containing the IL-2
proximal promoter driving expression of the luciferase
enzyme. Again, in order to examine Siva’s effect on IL-2
separate from Siva’s effect on apoptosis, we normalized IL-
2 transcriptional activity to viable cell counts. Siva overex-
pression inhibited IL-2 transcriptional activity (Figure 5A)
and Siva KD enhanced IL-2 transcription (Figure 5B).
FOXP3 and Siva repress endogenous IL-2 gene expression
In order to test whether FOXP3 and Siva functionally
interact to repress endogenous IL-2, we co-expressed
FOXP3 and Siva-1 in Jurkat cells by transduction with
Figure 4 Siva represses endogenous IL-2 gene expression. A. The flow plot gating scheme used in B and C is shown. An FSC high gate was
drawn to include 7AAD
pos cells, but exclude debris events that would falsely appear as viable, 7AAD
neg cells in subsequent analyses. 7AAD
neg
events included in the FSC high gate were used to calculate viable cell number. GFP is being detected in the YFP channel, which was not used
in any of these experiments. In B-D, IL-2 expression levels were divided by the mean viable cell number for each indicated sample. B. Flow plots
indicating viability and transduction efficiency based on GFP expression for Jurkat T cells transduced with pHSPG retrovirus (RV) or RV expressing
an EGFP/Siva-1 fusion protein (pHSP-EGFP/Siva-1). Transduced Jurkat T cells were subsequently tested for IL-2 production in response to PMA
and Ionomycin. C. Similarly to data shown in B, the flow plots show Jurkat T cells transduced with RV from pHSPG or pHSPG encoding untagged
Siva-1. IL-2 protein expression in response to PMA and Ionomycin for the same cells is shown. D. Knockdown (KD) of endogenous Siva with
shRNA enhanced endogenous IL-2 expression. Siva-1 KD efficiency was evaluated by standard RT-PCR and DNA bands are shown. In B-D, error
bars represent standard deviations for n = 3; * indicates p < 0.05 for two-tailed Student’s t-test between vector transduced cells and the
respective EGFP/Siva-1, Siva-1 or shSIVA expressing cells. Data shown in B-D is from one experiment representative of 3-5 replicates.
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Page 6 of 15pHSPG RV (Figure 6A). As expected, FOXP3 and Siva-1
each repressed endogenous IL-2 independently (Figure
6B). The combination of FOXP3 and Siva-1 failed to
repress IL-2 further than FOXP3 alone. We also exam-
ined the combined effects of Siva KD and exogenous
FOXP3 on IL-2. Figure 6C shows the efficiency of Siva
KD in Jurkat T cells transduced with pLKO LVs expres-
sing hairpin RNA against Siva or EGFP and PG RV
expressing FOXP3. Consistent with data shown above,
Siva KD enhanced IL-2 gene expression (Figure 6D).
FOXP3 effectively repressed IL-2 gene expression inde-
pendent of endogenous Siva expression levels. Thus, in
this experimental system, FOXP3-mediated repression
of endogenous IL-2 appears to be independent of Siva
gene expression levels.
Effect of FOXP3 and Siva on IL-2 promoter activity
In addition to evaluating the combined effects of FOXP3
and Siva on endogenous IL-2 gene expression, we inves-
tigated whether the two genes might functionally
interact to repress IL-2 transcriptional activity. First, we
tested the effect of FOXP3 and Siva-1 overexpression on
the transcriptional activity of the IL-2 proximal promo-
ter in the Jurkat T cell luciferase assay. We transfected
Jurkat T cells with the IL-2 reporter plasmid and differ-
ent combinations of pHSPG, pHSPG-Siva-1 and
pHSPG-FOXP3 in equal plasmid DNA mass. As indi-
c a t e db yt h ed a t ai nF i g u r e7 A ,b o t hSiva-1 and FOXP3
repress IL-2 transcriptional activityi n d e p e n d e n t l y .T h e
repressive effect of FOXP3 is stronger than Siva-1.W e
do not see an additive effect on IL-2 repression between
Siva-1 and FOXP3. In addition, we tested the combined
effect of Siva KD and FOXP3 overexpression on IL-2
transcriptional activity (Figure 7B). As expected, Siva
KD enhanced IL-2 transcriptional activity. However,
FOXP3 over expression masked the IL-2 enhancing
effect of Siva KD. Thus, similar to the endogenous IL-2
experimental results, the IL-2 transcriptional activity
assays suggest that FOXP3’s repressive effect masks the
repressive effect of Siva.
Figure 5 Siva represses IL-2 promoter activity. To evaluate IL-2 promoter activity, Jurkat T cells were transfected with an IL-2 luciferase
reporter plasmid plus other constructs to overexpress or KD Siva expression. IL-2 promoter-driven luciferase activity is expressed as a measure of
relative light units (RLUs) normalized to the viable cell number. A. Siva-1 overexpression with pHSPG-Siva-1 repressed IL-2-promoter activity. B.
Siva KD by shRNA had an enhancing effect on IL-2 promoter activity. *s indicate statistical difference compared to vector based on p < 0.05 by a
two-tailed Student’s t-test. These experiments were each performed twice and a result from one representative experiment is shown.
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Page 7 of 15Figure 6 Endogenous IL-2 in response to exogenous FOXP3 combined with Siva-1 overexpression or Siva knockdown.J u r k a tTc e l l s
were transduced with two rounds of RV or LV and then activated with PMA and Ionomycin. Following stimulation, cell viability was determined
using the gating method shown in Figure 4A and endogenous IL-2 expression was measured by ELISA. A. Flow cytometry for GFP expression
and viability in unstimulated Jurkat T cells transduced with different combinations of pHSPG (PG), PG-Siva-1, and PG-FOXP3 RV. Plots shown have
already been gated to exclude debris events using a gating scheme similar to the one shown in 4A. B. Endogenous IL-2 in response to FOXP3
and Siva-1 overexpression was determined using the cells shown in A. The IL-2 concentration was divided by the mean viable cell count for
each indicated sample. C. Siva KD efficiency was determined by quantitative realtime PCR for Siva and 18S in unstimulated Jurkat T cells
transduced with PG or PG-FOXP3 RV and pLKO-shEGFP or pLKO-shSIVA LV. The realtime PCR primers used in this experiment do not distinguish
between the two Siva isoforms. The error bars indicate standard deviation between technical replicates. #s indicate statistically significant
difference between the indicated bar and the adjacent, shEGFP-transduced control. D. Endogenous IL-2 in response to FOXP3 overexpression
and Siva KD, using the transduced Jurkat T cells described in C. *s indicate statistically significant difference between the indicated bar and the
PG- or shEGFP/PG-transduced control, in B and D, respectively. Statistically significant difference was based on p < 0.05 by a two-tailed Student’s
t-test. These transduction experiments were performed twice and representative experiments are shown.
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IL-2 is regulated by multiple transcription factors and
chromatin modifications [38,39]. We tested the effects
of Siva-1 and FOXP3 on the transactivating potential of
two major IL-2 transcriptional regulators, NFBa n d
NFAT. In these experiments, the reporter construct
contains a luciferase gene that is regulated by three tan-
dem repeats of either the NFB consensus sequence
from the MHC class I promoter [40] or the NFAT bind-
ing site from the human IL-2 gene promoter [41]. Con-
sistent with published reports and shown in Figure 8,
FOXP3 inhibits NFB [13] and NFAT [13,22] transacti-
vation potential in Jurkat T cells. Siva repressed NFB
(Figure 8A), but had no effect on NFAT activity (Figure
8B). The combination of FOXP3 and Siva-1 repressed
NFB activity more than FOXP3 alone. Even though the
NFB repressive effect of the two genes in combination
was slight (~20%), the effect was reproducible with sta-
tistical significance.
Discussion
In this report we have shown that FOXP3 and Siva phy-
sically interact. We have mapped the binding activities
to limited domains within each protein. FOXP3 and
Siva-1 both independently repressed IL-2 gene expres-
sion. One mechanism by which Siva-1 represses IL-2 is
via inhibition of NFB. In contrast, FOXP3 repressed
the activity of both IL-2 transactivators tested here,
NFB and NFAT. Although we did not reveal a func-
tional interaction between FOXP3 and Siva with regards
to IL-2 repression, the biophysical interaction invites
questions regarding how Siva might contribute to regu-
lation of FOXP3-expressing Treg cells.
The physical interaction was demonstrated through a
standard protein-protein interaction, Co-IP assay. Two
Siva isoforms have been identified and both Siva isoforms
interact with FOXP3. The Siva-2 isoform lacks the sec-
ond exon that encodes for the SAH and DDHR domains
[28,37], which were found to be dispensable for binding
Figure 7 IL-2 promoter activity in response to FOXP3 combined with Siva-1 overexpression or Siva knockdown. Similar to the data sets
shown above, the IL-2 promoter activity was normalized to viable cell counts. A. IL-2 promoter activity in response to FOXP3 and Siva-1
overexpression. In addition to the IL-2 luciferase reporter plasmid, Jurkat T cells were transfected with different combinations of pHSPG (PG), PG-
FOXP3, and PG-Siva-1. B. IL-2 promoter activity in response to FOXP3 overexpression and Siva knockdown. Jurkat T cells were transfected with
the IL-2 luciferase reporter, a plasmid containing either a negative control hairpin sequence (shNS) or shSiva, and PG or PG-FOXP3 plasmids
(RLUs, relative light units). *s indicate statistically significant difference between the designated bar and cells transfected with either PG in A or
shNS and PG in B. Statistically significant difference was based on p < 0.05 by a two-tailed Student’s t-test. These experiments were repeated
twice and data from one representative experiment is shown.
Hench and Su BMC Immunology 2011, 12:54
http://www.biomedcentral.com/1471-2172/12/54
Page 9 of 15FOXP3 in subsequent Siva truncation Co-IP experiments.
The Siva C-terminus, which encompasses both the puta-
tive B box and Zn F domains, contained FOXP3 binding
activity.
The Siva C-terminus is enriched with cysteine residues
that could be important to the protein’s tertiary structure
and function. Paired cysteine residues are associated with
intramolecular disulfide bond formation. The Siva C-ter-
minus contains six paired cysteine residues. Nestler et al
[42] used truncation mutants to show that Siva coordi-
nates three zinc ions, two of which are associated with the
C-terminus [42]. Although a few groups have found that
the Siva C-terminus is necessary to interact with other
binding partners [43-45], no one has described whether
specific C-terminal point mutations block Siva function.
Future site-directed mutagenesis studies of the Siva C-
terminal cysteine residues could be informative to further
characterize the physical interaction between Siva and
FOXP3.
FOXP3’s Siva-binding activity is contained within a
broad central region that includes the zinc finger, the
leucine zipper and the RUNX1 binding domain (amino
acids 106-332). Mutants missing either the first 105 N-
terminal amino acids or the C-terminal forkhead domain
sustained binding to Siva-1. Further experiments are
needed to define a minimal region of FOXP3 involved in
binding to Siva-1. The FOXP3 leucine zipper domain is
required for homodimerization, IL-2 repression, and Treg
suppressive function [11,21,46]. Given that the leucine
zipper domain is within the region that binds Siva-1, one
question we are interested in addressing in the future is
whether known leucine zipper IPEX mutations (Δ250,
Δ251)[11,21] interfere with FOXP3 binding to Siva-1.
One limitation of this study was that technical chal-
lenges obstructed our efforts to detect a biophysical
interaction between endogenously expressed FOXP3 and
Siva. Also, we have not yet performed sufficient experi-
ments to address whether the biophysical interaction
could be linked to any functional interaction. In order to
test whether the biochemical interaction between FOXP3
and Siva-1 affects their functional interaction, a minimal
region of biochemical interaction for at least one protein
Figure 8 NFB and NFAT reporter activity in response to Siva-1 and FOXP3 overexpression. Jurkat T cells were transfected with NFB and
NFAT luciferase reporter plasmids and expression plasmids encoding FOXP3 or Siva-1 or the parental vector control, pHSPG (PG) (RLUs, relative
light units). A. Both FOXP3 and Siva-1 repress NFB activity in response to PMA and Ionomycin. B. FOXP3 repressed NFAT activity in response to
PMA and Ionomycin. *s indicate statistically significant difference between the indicated bar and the PG vector control based on p < 0.05 by a
two-tailed Student’s t-test. ** indicates statistically significant difference between Siva-1 and FOXP3 in combination compared to FOXP3 alone.
These experiments were repeated twice and data from one representative experiment is shown.
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IP experiments for at least one of the proteins could be
informative towards defining the relationship between
the biophysical interaction and any proposed functional
interaction for FOXP3 and Siva-1.
Our initial hypothesis was that FOXP3 and Siva-1
might functionally interact to repress IL-2 gene expres-
sion. We did not observe an additive repressive effect
between FOXP3 and Siva-1 on IL-2 gene expression.
Instead, our data suggests that FOXP3 might be a domi-
nant suppressor that masks the repressive effects made
by Siva-1 on IL-2 gene expression.
Our analysis of two IL-2 transactivators supports the
assertion that Siva-1 and FOXP3 affect shared and differ-
ent IL-2 regulatory mechanisms. Consistent with pre-
vious reports, FOXP3 repressed NFB[ 2 2 ]a n dN F A T
[13,22] transactivation reporters. Siva-1 inhibited NFB,
but had no effect on NFAT in cells stimulated with PMA
and Ionomycin. We observed a small, but significant
additive repressive effect between FOXP3 and Siva-1 on
NFB activity.
The NFB-repressive effects that we observed for
FOXP3 and Siva-1 are consistent with published reports.
The effects of each gene on NFB activity may be parti-
tioned into distinct cytoplasmic and nuclear signalling
events. In resting cells, cytoplasmic IBa sequesters the
canonical NFB subunits p65 and p50, preventing their
nuclear translocation. In response to stimulus, IBa
breaks down and releases the NFB subunits, which
translocate to the nucleus [47]. Siva blocked NFB
nuclear accumulation via stabilization of cytoplasmic
IBa [36]. On the other hand, FOXP3 blocked NFB
transactivation potential by mechanisms independent of
nuclear translocation and DNA binding [13]. Further,
our group showed that FOXP3’s promoter-dependent
effects on NFB transactivating potential were indepen-
dent of nuclear translocation. FOXP3 enhanced HIV-1
gene expression by increasing the amount of NFBp 6 5
subunit bound to the LTR (long terminal repeat) [10]. To
summarize, in separate experimental systems, inhibition
of NFB activity by Siva has been shown to occur
upstream of IBa degradation and nuclear translocation,
whereas FOXP3 inhibits NFB activity downstream of
IBa degradation. The biophysical interaction that we
have presented suggests that another regulatory mechan-
ism could be occurring that would involve co-localization
of FOXP3 and Siva-1 within the same subcellular
compartment.
Given that Siva has displayed both nuclear and cytoplas-
mic subcellular localization [43,48-51], the possibility
remains that Siva could regulate gene transcription from
within the nucleus in addition to its cytoplasmic effect on
NFB. As of yet, published reports of a nuclear specific
function for Siva are lacking. Most detailed investigations
of Siva function have examined Siva in relation to trans-
membrane signalling molecules or mitochondrial-asso-
ciated apoptosis regulators thought to be present in the
cytoplasm, not in the nucleus [28,29,37,43,44,50,52-54]. In
future studies, it will be interesting to look into whether
Siva displays nucleus-specific activities such as direct bind-
ing to DNA or chromatin.
Conclusions
To conclude, we have carried out an analysis of IL-2 gene
regulation by FOXP3 and Siva in Jurkat T cell lines.
FOXP3 and Siva both repress IL-2 gene expression inde-
pendently, though the repressive effect of FOXP3 appears
to be dominant over Siva in both assays used here. We
have shown that FOXP3 and Siva appear to have a slight,
but significant, additive repressive effect on NFB activity.
Many questions remain, most importantly, those regarding
Siva’sc o n t r i b u t i o nt oT reg development and function.
Additional efforts are needed to address these intriguing
possibilities.
Methods
Cell culture and plasmids
293T cells were grown in DMEM-10% FetalPlex
(Gemini). Jurkat cells were grown in RPMI 1640-10%
fetal bovine serum supplemented with 2 mM L-gluta-
mine, 100 U/ml penicillin, and 100 mg/ml streptomycin.
When needed, Jurkat cells were selected in 1 μg/ml pur-
omycin (puro). Puro selection took 3-10 days, depending
on the transduction efficiency. Puro selection was
judged to be complete once cellular debris events mea-
sured by Gauva EasyCyte reached less than 10%. Unless
otherwise stated, all tissue culture reagents were pur-
chased from Invitrogen.
Myc/FOXP3 full length and all derivative truncation
mutants were expressed in pCDNA3.1 and made as pre-
viously described [10].
The human Siva-1 cDNA clone [corresponding to Gen-
Bank: NM_006427] was purchased from ATCC (ATCC#:
MGC-17039). By PCR subcloning, we transferred Siva-1
from pCMV-SPORT6 into pEGFP-C1 to generate an
enhanced green fluorescent protein (EGFP)/Siva-1 fusion
construct. All Siva truncation mutants were derived from
pEGFP/Siva-1 by PCR subcloning. The splice overlap
extension method was used to generate the Siva-2 [Gen-
Bank: NM_021709] and ΔB box mutants [55]. Siva-1 was
subcloned into the pHSPG retroviral vector under control
of the MSCV promoter [56]. pHSP-EGFP/Siva was gener-
ated by replacing the EGFP cassette with EGFP/Siva under
control of the PGK promoter.
A panel of five pLKO lentiviral (LV) vectors expressing
short hairpin targets against Siva was purchased and
tested for knockdown (KD) efficiency (Open Biosystems).
All shSIVA KD experiments in this report used Open
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puro selection cassette and the U6 promoter controls
hairpin expression. pLKO-shEGFP and pLL5.0-NS served
as a negative controls in designated experiments. Dr.
James Bear’s lab provided the pLL5.0-NS construct [57].
The IL-2 and NFAT luciferase reporters were originally
acquired from Dr. Gerald Crabtree’s lab [41]. Dr. Albert
Baldwin provided us with the NFB luciferase reporter, a
construct that was originally designed by Dr. Bill Sug-
den’s group [40,58].
Yeast two-hybrid screen
A human thymus cDNA library was screened for FOXP3
binding partners. The bait plasmid contained the full
length FOXP3 sequence in-frame with the Gal4 DNA
binding domain (BD). The prey plasmids contained
human thymus library cDNA clones adjacent to the Gal4
activation domain (AD). cDNA clones were amplified
using random primers and oligo (dT) primers to generate
partial and full-length cDNA clones, respectively. Interac-
tion between the DNA-BD and AD permits transcription
of reporters for histidine (His), adenine (Ade), and b-galac-
tosidase (b-gal) synthesis. His-/Ade- dropout media and
blue/white screening for b-gal activity permitted selection
of clones containing FOXP3 interacting partners. Another
level of selection criteria was provided by increasing doses
of the histidine production inhibitor, 3-Amino-1,2,4-tria-
zole (3-AT).
Mouse Siva gene expression analysis based on microarray
data
We used microarray data from Fontenot et al. [33] to
determine Siva expression levels in mouse T cell subsets.
Accordingly, CD4
pos T cells from the Foxp3
GFP mouse
were sorted based on Foxp3
GFP and CD25 surface
expression. The dataset, “CD4+ T cells expressing tran-
scription factor Foxp3 and various amounts of CD25”
(GDS1113 record), was accessed through NCBI’sG E O
database [59].
T h eA f f y m e t r i xM o u s eG e n o m e4 3 02 . 0a r r a yu s e di n
this study includes four spots representing Siva. Each spot
contains 11 probes. In order to determine which spots
were likely to reveal the most accurate Siva gene expres-
sion profile, we investigated where each individual probe
aligned to the mouse genome. We accessed the UCSC
genome browser via the NetAffx™ Analysis Center and
observed probe alignment locations throughout the mouse
genome. A few probes aligned to regions outside of the
Siva coding region on chromosome 12. We determined
the ratio of correct to incorrect probe alignments (# of
Siva-aligning probes/# of probes aligning to non-Siva
regions) and discarded spots with a ratio less than 2. The
spots shown in this report, 1426323_X_AT and
1452020_A_AT, exhibited ratios of 3 and 7, respectively.
293T transfections, Co-IPs, and antibodies
293T cells were co-transfected with Effectene according to
the manufacturer’s protocol (Qiagen). 4 μg total plasmid
DNA was added to sub-confluent cells in 10-cm dishes. At
48-hours post-transfection, lysates were harvested in PBS,
washed once and stored at -20°. Cell pellets were lysed in
modified RIPA (Tris-HCl, pH 7.35, 50 mM; NaCl,
150 mM; EDTA, 1 mM; NP-40 1%; NaDeoxycholate
0.25%) supplemented with Complete EDTA-free Protease
Inhibitor (PI, Roche), phenylmethylsulfonyl fluoride
(PMSF, 100 mM), and sodium fluoride (NaF, 50 mM).
Immunoprecipitations (IPs) were performed in ~1 ml total
volume PBS (supplemented with PI, PMSF and NaF).
500 μg protein lysate and 40 μl mouse anti-Myc 9E10
h y b r i d o m as u p e r n a t a n t( k i n d l yp r o v i d e db yD r .Y u e
Xiong) were added to PBS. The protein lysate comprised
5-10% of the IP volume. IPs were incubated on a rotator
at 4° overnight. Inputs were mixed with SDS loading dye
and stored at 4°. A 1:1 mixture of Immobilized Protein A
(Invitrogen) and Protein G Agarose (ThermoScientific)
beads was prepared and washed three times with PBS.
40 μlo fb e a dm i x t u r ew e r ea d d e dt oe a c hI P .I P sw i t h
beads were incubated 2-4 hours at 4° on a rotator. Beads
were washed four times with cold PBS (no supplements).
Washed beads were resuspended in 20 μl SDS loading dye
and heated to boiling in a 95° sand bath (~10 minutes).
Boiled samples were run on 10% NuPage minigels accord-
ing to the manufacturer’s instructions (Invitrogen). Fol-
lowing transfer, PVDF membranes were blocked with
PBS-Tween (0.2% Tween, 5% milk), which was used for all
subsequent antibody incubation steps. Membranes were
incubated with mouse a-GFP (Clontech, Living Colors A.
v. Monoclonal Antibody (JL-8), 100 ng/ml) to detect
immunoprecipitation of EGFP/Siva fusion constructs.
Membranes were stripped and reprobed with rabbit a-
M y cs e r a( A l s o ,p r o v i d e db yD r .Y u eX i o n g ) .
Standard RT PCR and quantitative PCR
The Qiagen RNeasy isolation kit was used to isolate
mRNA from frozen cell pellets preserved at -80° in Qiagen
RLT buffer containing b-mercaptoethanol. Reverse tran-
scription reactions were performed with random primers
and M-MLV reverse transcriptase in the presence of
RNase inhibitor. The following primer sequences were
used in semi-quantitative RT PCRs: Siva For,5 ’-T A C
AGCTCAAGGTCCGCGTGA GC-3’, Siva Rev,5 ’-TCAC
TGCAGTCCACGAGGCCACA-3’, b-actin For,5 ’-T C A
CCCACACTGTGCCCATCTACGA-3’, b-actin Rev,5 ’-
CAG CGGAACCGCTCAT TGCCAATGG-3’. Quantita-
tive Taq-Man PCR was performed using primers from
Applied Biosystems. For 18S PCRs, cDNA templates were
diluted 1:1000. Relative quantities were determined by cor-
relating CT values to a standard curve. Relative Siva quan-
tities were normalized to the relative 18S quantity.
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Retroviral (RV) and lentiviral (LV) supernatants (SN)
were produced by using the calcium phosphate method
to transfect 293T cells with pHSPG, VSV-G, and gag/pol
plasmids [60]. SN’s were collected at 48 and 72 hours
and titered on Jurkat cells by spinoculation, as has been
described [56]. Efficiency of infectivity was determined
based on %GFP expression using a Gauva EasyCyte flow
cytometer. For subsequent experiments, the %-infected
was used to calculate the volume of RV SN needed to
obtain 99% transduction efficiency for a fixed cell num-
ber. Dual transductions with pHSPG-Siva-1 and pHSPG-
FOXP3 RV were performed as follows. A fixed number
of cells was transduced with either pHSPG or pHSPG-
Siva-1 on day 0. Two days later, high transduction effi-
ciency was confirmed, the cells were counted and equal
cell numbers were distributed and mixed with RV for
either pHSPG or pHSPG-FOXP3. Since both sets of RV
use GFP to mark transduction efficiency, GFP
neg Jurkat
cells were transduced in parallel to control for transduc-
tion efficiency.
In Siva KD experiments, Jurkat T cells were transduced
with pLKO-shEGFP or pLKO-shSiva LV and selected in
puromycin (see Cell culture and plasmids above). Next,
the same cells were transduced with PG or PG-FOXP3
RV.
IL-2 ELISA
To evaluate endogenous IL-2, transduced Jurkat T cells
were distributed in 96-well plates at a concentration of 2 ×
10
5 cells/well. Cells were activated with phorbol 12-myris-
tate 13-acetetate (PMA, 25 ng/ml) and Ionomycin (1 μM).
At the end of ~18 hours, cell viability was evaluated on a
Gauva EasyCyte. Plates were spun down and supernatants
were collected and stored at -20°. IL-2 concentrations
were determined with a BD OptEIA™ Human IL-2 ELISA
kit.
Jurkat transfections and luciferase reporter assays
In order to perform luciferase assays, Jurkat cells were
transfected by electroporation in cytomix buffer [61]. Jur-
kat cells were harvested, counted and redistributed to
yield 5 × 10
6 cells/transfection. Cells were washed once in
PBS before being suspended in cytomix buffer supplemen-
ted with fresh 2 mM ATP (300 μl buffer/transfection).
While cells were being washed, plasmid DNA was pre-
pared: 1 μg reporter plasmid (see Cell culture and plas-
mids above) was mixed with differing amounts of plasmid
expressing genes of interest or the vector control (10 μg
DNA total). Cells in cytomix buffer were mixed with DNA
mixtures and transferred to cuvettes on ice (Biorad Gene
Pulser Cuvette, 0.4 cm). A Biorad Gene Pulser Xcell was
used to electroporate cells at 300 V, 500 μF, and infinite
resistance. Immediately following electroporation of all
samples, the shocked cells were diluted in pre-warmed
culture media (RPMI 10% FBS described above). Cells
were cultured in 6-well plates. After resting for 12-24
hours, cells were distributed into 96-well plates and acti-
vated with PMA, 25 ng/ml and ionomycin, 1 μM. Dura-
tion of activation ranged from 6-12 hours. At the assay
endpoint, 20 μl/well was removed to measure viability and
transfection efficiency on a Gauva EasyCyte mini flow cyt-
ometer. Plates were spun and cells were washed once with
PBS to remove growth media. Cells were lysed in 45 μl1 ×
Promega Reporter Lysis Buffer and frozen at -80°. Plates
were read on a Veritas Microplate Luminometer according
to the manufacturer’s instructions. The amount of promo-
ter-driven reporter activity was expressed as a measure of
relative light units (RLUs).
Statistical analysis
A two-tailed Student’s t-test was used to evaluate statis-
tical difference between experimental treatments and a
p-value < 0.05 was set as the cut-off for statistically sig-
nificant difference.
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